Core Insights - Teleflex Incorporated has launched two initiatives to raise awareness about benign prostatic hyperplasia (BPH) during Men's Health Month, focusing on quality-of-life issues and potential rectal toxicity from prostate cancer radiation treatment [3][8]. Group 1: Awareness Initiatives - The initiatives include the "Prostate Monster" ad campaign and the Prostate Education Express, a mobile training center that will tour major U.S. cities throughout 2025 [4][5]. - The Prostate Education Express aims to educate both physicians and the community about BPH and the benefits of the UroLift™ System and Barrigel™ rectal spacer [4][7]. Group 2: UroLift™ System - The UroLift™ System is a minimally invasive treatment for BPH symptoms, indicated for men aged 45 and older, and has been used to treat over 500,000 men globally [10][6]. - A clinical study showed a low retreatment rate of about 2-3% per year, indicating the durability of the UroLift™ System [10]. Group 3: Barrigel™ Rectal Spacer - Barrigel™ rectal spacer is the first hyaluronic acid rectal spacer designed to protect the rectum during radiation therapy for prostate cancer, with over 50,000 men treated [12][8]. - A clinical study found that 98.5% of men treated with Barrigel™ achieved at least a 25% reduction in radiation to the rectum, with an average reduction of 85% [8].

Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3 First Study to Confirm Safety of Stabilized Hyaluronic Acid (sHA) Rectal Spacer in Cases with Rectal Wall Infiltration (RWI).4 WAYNE, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Teleflex Inc ...